PR: Heidelberg Pharma to Present at the Upcoming Virtual European Biotech Investor Day 2020

PRESS RELEASE

Heidelberg Pharma to Present at the Upcoming Virtual European Biotech Investor Day 2020

Ladenburg, Germany, 24 June 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that Prof Andreas Pahl, Chief Scientific Officer, plans to present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020, taking place on 25th June 2020 and hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.

Details of the presentation:

ATACs fighting Cancer

Date: 25th June 2020 at 11.00 am EDT / 05.00 pm CEST

Access to the presentation:https://www.webcaster4.com/Webcast/Page/2408/35374 Archive of the event will be available on the Company's website athttps://heidelberg-pharma.com/en/press-and-investors/calender-and-presentations/presentations

About Heidelberg Pharma's proprietary ATAC technology

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available atwww.heidelberg-pharma.com.

Contact	IR/PR support
Heidelberg Pharma AG	MC Services AG
Corporate Communications	Katja Arnold (CIRO)
Sylvia Wimmer	Managing Director & Partner
Tel.: [phone]	Tel.: [phone]
E-Mail: investors[at]hdpharma.com	Mobil: [phone]
Schriesheimer Str. 101, 68526 Ladenburg	E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.